Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase Ib/ll Clinical Study to Evaluate Safety and Dosing of Humanised Monoclonal Antibody CA9hu-1 to Human Carbonic Anhydrase IX in Patients With Advanced Solid Tumours

Next Previous
Trial Profile

Phase Ib/ll Clinical Study to Evaluate Safety and Dosing of Humanised Monoclonal Antibody CA9hu-1 to Human Carbonic Anhydrase IX in Patients With Advanced Solid Tumours

Status: Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Mar 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CA9hu 1 (Primary)
  • Indications Head and neck cancer; Malignant-mesothelioma; Non-small cell lung cancer; Renal cell carcinoma; Triple negative breast cancer
  • Focus Adverse reactions
  • Acronyms CAMP1
  • Sponsors Mabpro

Most Recent Events

  • 14 Mar 2023 Planned End Date changed from 1 Jan 2026 to 1 Jan 2027.
  • 14 Mar 2023 Planned primary completion date changed from 1 Jan 2025 to 1 Jan 2026.
  • 14 Mar 2023 Planned initiation date changed from 1 Jan 2023 to 1 Jan 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top